Scottish Medicines Consortium agrees to use of Rinvoq
Therapy will now treat adults across Scotland with moderate rheumatoid arthritis
Read More
Tag: RA
GSK launches PhIII programme for otilimab in RA
The Phase III clinical programme is the first in RA to include head-to-head comparisons of otilimab with current treatments across all pivotal studies
Read More
US approves Lilly/Incyte’s Olumiant
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Read More
Sanofi’s Kevzara will be funded for NHS use
Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.
Read More
Janssen’s Plivensia given thumbs down by US advisors
US regulatory advisors are not recommending approval of Johnson & Johnson’s Plivensia for rheumatoid arthritis, having concluded – based on the data available – that the benefits of the drug do not outweigh the potential risks.
Read More
NICE backs Lilly’s JAK inhibitor Olumiant for RA
A novel treatment option for some patients with rheumatoid arthritis (RA) could soon be routinely available on the NHS, after cost regulators ruled Eli Lilly’s Olumiant to be cost-effective with the inclusion of a confidential patient access scheme.
Read More
Novartis’ MabThera biosimilar wins EU nod
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
Read More
Green light for Sanofi, Regeneron’s Kevzara
Sanofi and Regeneron’s Kevzara has been cleared in the US to treat moderately to severely active rheumatoid arthritis (RA) in adult patients.
Read More
UK launch for Nordic’s novel methotrexate pen
Nordic Pharma has launched Nordimet – the first button-free, once-weekly PEN device containing the active substance methotrexate – across the UK, offering patients with various auto-immune conditions a new means of administering treatment with a Disease Modifying Anti-Rheumatic Drug (DMARD).
Read More
Pfizer bags approval for RA drug Xeljanz
Some patients with moderate to severe forms of rheumatoid arthritis could get access to a new treatment option in Europe following the approval of Pfizer’s oral Janus kinase (JAK) inhibitor Xeljanz.
Read More
Lilly/Incyte’s Olumiant bags first approval with EU nod
Eli Lilly’s Olumiant has picked up its first regulatory approval with a nod from the European Commission to treat moderate-to-severe active rheumatoid arthritis.
Read More
GSK files RA drug in the EU
GlaxoSmithKline has filed an application in Europe seeking approval to market its investigational human anti-interleukin (IL)-6 monoclonal antibody sirukumab for the treatment of rheumatoid arthritis (RA).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
